Advertisement
Advertisement
BioLife Solutions, Inc. (BLFS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
As of 04:00PM EDT. Market open.
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 12.09 |
| Open | 12.57 |
| Bid | 7.50 x 1000 |
| Ask | 20.01 x 800 |
| Day's Range | 11.99 - 12.91 |
| 52 Week Range | 10.40 - 60.67 |
| Volume | |
| Avg. Volume | 446,375 |
| Market Cap | 535.579M |
| Beta (5Y Monthly) | 1.75 |
| PE Ratio (TTM) | 98.17 |
| EPS (TTM) | 0.13 |
| Earnings Date | Mar 21, 2022 - Mar 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 38.88 |
- Zacks
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Lags Revenue Estimates
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
BioLife Solutions Reports First Quarter 2022 Financial Results
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced financial results for the three months ended March 31, 2022.
- Zacks
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 30% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
